In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Kintara Therapeutics (KTRA – Research Report). The company’s shares opened today at $0.09.
McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -39.6% and a 14.32% success rate on recommended stocks.
Kintara Therapeutics has an analyst consensus of Hold.
See Insiders’ Hot Stocks on TipRanks >>
KTRA market cap is currently $8.41M and has a P/E ratio of -0.27.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Read More on KTRA: